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The association between hypertension and chronic renal
disease is well known. The pathogenesis of hypertension in
patients with chronic kidney disease (CKD) is complex and
multifactorial, which may explain why it is resistant to
treatment. The traditional paradigm is that hypertension in
CKD is due either to an excess of intravascular volume
(volume dependent) or to excessive activation of the
renin–angiotensin system in relation to the state of sodium/
volume balance (renin-dependent hypertension). This review
focuses on the importance of less established mechanisms,
such as increased activity of the sympathetic nervous system,
increased endothelin production, decreased availability of
endothelium-derived vasodilators and structural changes of
the arteries, renal ischemia, and sleep apnea.
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The association between hypertension and chronic renal
disease is well known and renal diseases are by far the most
common cause of secondary hypertension. The pathogenesis
of hypertension in patients with chronic kidney disease
(CKD) is complex and multifactorial, which may explain why
it is resistant to treatment. The traditional paradigm is that
hypertension in CKD is due either to an excess of
intravascular volume (volume dependent) or to excessive
activation of the renin–angiotensin system in relation to the
state of sodium/volume balance (renin-dependent hyper-
tension) (Table 1). In recent years, this concept has been
challenged owing to the recognition that interventions aimed
at reducing blood volume and inhibiting the renin–angio-
tensin system often do not normalize blood pressure (BP),
and the unraveling of alternative pathogenic mechanisms
(Table 1). Among these are increased activity of the
sympathetic nervous system (SNS), increased endothelin
(ET) production, decreased availability of endothelium-
derived vasodilators/endothelial dysfunction, structural
changes of the arteries, renal ischemia, and sleep apnea. In
addition, pharmacological interventions aimed at treating the
primary renal disease or some of its consequences, such as
the use of cyclosporine, steroids, calcium with vitamin D,
sympathomimetic agents, erythropoietin, and non-steroidal
anti-inflammatory agents, may contribute to sustaining or
aggravating hypertension in CKD patients.
This review will not address well-established mechanisms,
such as sodium retention and activation of the renin–angio-
tensin system, both of which have been extensively reviewed.1
The review will also not address the role of obesity and the
metabolic syndrome in hypertension and renal disease, which
would require a separate extensive discussion. We will instead
emphasize the importance of less established mechanisms,
with the belief that therapeutic interventions aimed at those
alternative mechanisms may represent the key for adequate
BP control in many CKD patients.
ROLE OF INCREASED SNS ACTIVITY
Increased SNS activity has been demonstrated in diverse
experimental models,2,3 as well as in patients with renal
disease.4 Animal studies have shown that the kidney is not
only an elaborate filtering device but also a sensory organ,
richly innervated with sensory and afferent nerves. Thus, in
addition to being the target of the SNS activity, the kidney
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can also be the origin and modulator of this activity. There
are two main functional types of renal sensory afferent nerve
fibers: (a) hard and sensitive fibers, which increase their firing
in response to changes in renal perfusion and intrarenal
pressure and (b) chemosensitive fibers, which are stimulated
by ischemic metabolites or uremic toxins.5 The activation of
these fibers may establish connections with integrative nuclei
of the SNS in the central nervous system.6,7 In experimental
animals, stimulation of these afferent nerves by either
ischemic metabolites such as adenosine, or by uremic toxins
such as urea, evokes reflex increases in SNS activity and BP.5
Chronic stimulation of these afferent nerves may lead to SNS
overactivity and hypertension. This suggests that ischemic
injury to the kidneys, owing to macro- or microvascular
disease, may cause hypertension through the activation of
these chemosensitive fibers.
Our studies on 5/6 nephrectomized (NPX) rats have
provided the most convincing evidence for a role of the SNS
in the pathogenesis of hypertension associated with kidney
disease. The turnover rate8 and the secretion of norepine-
phrine (NE)9 from the posterior hypothalamic nuclei were
greater in NPX than in control rats. Bilateral dorsal
rhizotomy at the level T-10 to L-3 prevented the increase in
BP and NE turnover in the posterior hypothalamic nuclei.
These studies led us to postulate that increased renal sensory
impulses generating in the affected kidney and then
transmitted to the central nervous system activate brain
regions involved in the noradrenergic control of BP resulting
in hypertension. This concept is supported by studies in
human subjects with end-stage renal disease (ESRD).
Converse et al.4 observed increased muscle sympathetic nerve
activity (MSNA) and peripheral vascular resistance in
hypertensive patients with ESRD. Bilateral NPX patients,
on the other hand, manifested lower MSNA, BP, and
peripheral vascular resistance compared to patients with
native kidneys. In all, these findings support the notion that
increased afferent nervous input from the kidney to the
central nervous system may play an important role in the
pathogenesis of hypertension in CKD and ESRD patients.
In our laboratory, we have developed a model of
neurogenic hypertension caused by renal injury without
measurable alterations in kidney function. In this model, the
injection of 50 ml of phenol in the lower pole of one kidney
causes an immediate and persistent elevation of BP and SNS
activity in the rat; renal denervation prevents these effects.9
The studies in the 5/6 NPX rat model, ESRD patients and the
‘phenol–renal injury model’ have clearly demonstrated that
renal injury may activate renal afferent pathways and result in
SNS activation and hypertension (Figure 1). Locally released
angiotensin II appears to mediate central activation of SNS
activity, as specific angiotensin II AT-1 receptor antagonists
abrogate SNS activation caused by renal injury in the rat.10
One important primary event leading to increased SNS
activity is probably renal ischemia. In patients with
renovascular hypertension, Miyajima et al.11 demonstrated
increased levels of MSNA compared to patients with essential
hypertension. Restoration of renal perfusion with renal
angioplasty reduced MSNA and BP in these patients.
Ligtenberg et al.12 observed an increase in MSNA in patients
with CKD and renin-dependent hypertension, when com-
pared with controls, and Klein et al.13 observed increased
MSNA in hypertensive but not in normotensive patients with
Table 1 | Factors implicated in the pathogenesis of
hypertension in kidney disease
Traditional factors
Sodium retention and volume excess
Activation of the renin–angiotensin system
Less recognized factors
Activation of the sympathetic nervous system
Renal ischemia
Sleep apnea
Deficit of endothelium-derived vasodepressor substances
Increased endothelin production
Reduced central dopaminergic tone
Reduced baroreceptor sensitivity/abnormal vagal function
Aldosterone
Oxidative stress



























Figure 1 | This schema summarizes current concepts linking renal
damage with increased sympathetic nervous system (SNS)
activity. Renal damage/ischemia stimulates afferent pathways, which
integrate with key brain structures involved in the noradrenergic
control of blood pressure. The central mediator of this pathway
appears to be angiotensin II, which stimulates SNS activity through
specific angiotensin-1 (AT1) receptors. Specific blockers of these
receptors abrogate central SNS activation mediated by renal injury.
Efferent SNS pathways may cause hypertension and contribute to
cardiovascular and renal damage.
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polycystic kidney disease regardless of kidney function. One
potential mechanism for cyclosporine-induced hypertension
is through activation of renal afferent pathways, which result
in the activation of efferent sympathetic nerves and decreases
fractional excretion of sodium.14
Other mechanisms potentially responsible for the increase
in SNS activity in uremic patients include reduced central
dopaminergic tone,15 reduced baroreceptors sensitivity,16
abnormal vagal function,17 increased plasma b-endorphin
and b-lipotropin,18 and increased serum leptin levels.19
The increased activity of the SNS does not only contribute
to hypertension but it may also contribute to the progression
of kidney disease and cardiovascular mortality in ESRD
patients. Amann et al.20 observed that proteinuria and the
development of glomerulosclerosis were significantly attenu-
ated by sympatholytic drug in subtotally NPX rats. Zoccali
et al.21 have shown a correlation between blood levels of NE
and cardiovascular mortality in ESRD patients.
For the reasons exposed above, antiadrenergic drugs
should be an important component of hypertension manage-
ment in CKD patients. Of note, angiotensin-converting
enzyme inhibitors and angiotensin receptor blockades
partially reduce SNS activity, by interfering with effects of
angiotensin II on SNS transmission both at peripheral and
central sites.
SLEEP APNEA AND CIRCADIAN VARIABILITY OF BLOOD
PRESSURE IN CKD
Sleep apnea is common among CKD patients and it may
contribute to abnormal circadian BP variability, hypertension
and cardiovascular disease.22 Normally, BP tends to be the
highest during the morning, gradually decreases during the
course of the day and reaches the lowest levels at night.
Approximately 10–25% of patients with essential hyper-
tension does not display the normal nocturnal dipping of BP
and are called ‘non-dippers’, as opposed to those with a
normal circadian rhythm who are called ‘dippers’. Among
CKD patients,23 and those on maintenance hemodialysis,24
the prevalence of non-dippers is 74–82%. Sometimes, in these
patients, BP during the night can be greater than that
measured during the day (nocturnal hypertension). The
phenomena of non-dipping and nocturnal hypertension have
been associated with greater risk of cardiac concentric
hypertrophy, and cardiovascular events in ESRD patients.25
Several mechanisms may be responsible for the pheno-
mena of non-dipping in patients with CKD including
extracellular volume expansion, uremic neuropathy, and
restless leg syndrome. However, sleep disordered breathing
also seems to play an important role. Oxygen desaturation,
triggered by sleep apnea, occurs in 21–47% of ESRD patients,
and it may contribute to raising BP through the activation of
chemoreceptors connected with the SNS. Removal of
excessive volume with dialysis26 or treatment with nasal
continuous positive pressure may improve nocturnal oxygen
desaturation, and reduce SNS activity and BP in these
patients.27
ROLE OF THE VASCULAR ENDOTHELIUM
The role of the endothelium in vascular and renal physiology
and pathology is well recognized. A number of investigators
have speculated that an altered balance between endo-
thelium-derived relaxing factors and endothelium-derived
constricting factors may play a role in hypertension
associated with kidney disease.28
ENDOTHELIUM-DERIVED VASOCONSTRICTOR FACTORS
The role of ET in CKD-related hypertension has been the
focus of active research and controversy. Two distinct
complementary DNAs of ET receptors have been identified.
The ET-A receptor is predominately expressed on vascular
smooth muscle cells, where its action mediates vasoconstrict-
ion. The ET-B receptor is predominately found on endo-
thelial cells, where its action promotes vasodilation via
the release of nitric oxide (NO) and prostacyclin.29 ET-1’s
affinity for the ET-A receptor is the greatest (ET-14ET-2
4ET-3), likely related to its almost irreversible binding to
the receptor lasting greater than 2 h. ET-B receptors have
equal affinity for all three isoforms.
ETs have a variety of actions, some of which are related to
the maintenance of vascular tone. The role of ET in the
regulation of vascular tone has been studied in animal and
human models through the use of selective receptor
antagonists.30 ET-A blockade results in vasodilatation,
probably as a result of an increase in NO generation. By
contrast, blockade of ET-B receptors results in vasoconstrict-
ion, indicating that there is a balance between the two
receptor actions.31 In addition to its contractile actions on
vascular smooth muscle, ET can also modulate SNS
activity.32
Some controversy exists whether ET secretion exerts a
primary role in hypertension or whether it is the result of
vascular injury caused by the shear stress or by vasoconstrict-
ors. Cytokines, thrombin, vasoactive hormones such as
epinephrine, vasopressin and angiotensin II, and oxidative
stress stimulate ET release from endothelial cells, suggesting a
secondary role. Interestingly, angiotensin II’s stimulation of
ET-1 release has been shown to be mediated by oxidative
stress. Ortiz et al.33 infused angiotensin II chronically causing
hypertension in rats, all of which were blocked by both an
antioxidant and ET receptor blockade.
ET may also exert effects on renal tubular sodium
handling. The predominant receptor in the kidney is the
ET-B receptor,34 and its activation results in natriuresis. ET-B
receptor antagonists exacerbate hypertension in high salt diet-
fed rats, although ET-A blockade reverses the hypertension to
normal.35 It has also been shown that ET-B receptor-deficient
rats develop salt-sensitive hypertension.36
Increased plasma ET-1 levels have been shown in patients
with essential hypertension by some investigators37 but not
by others.38 The systemic levels may not be as important
given that ET is released on the basolateral surface and exerts
its effect in a paracrine and autocrine manner on nearby
endothelial and smooth muscle cells. Hypertensive patients
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with CKD39 and ESRD40 display higher plasma levels of ET-1
and ET-3 than normotensive subjects. It is unclear whether
this is the result of the uremic state or the exposure of blood
to an extracorporeal circuit during hemodialysis. ET receptor
antagonists have been shown to significantly reduce BP in
patients with essential hypertension41 and to reduce blood
pressure and proteinuria in CKD patients.42 The place of ET-1
antagonists in the management of hypertension in CKD and
ESRD patients remains to be further explored.
ENDOTHELIUM-DERIVED VASODILATOR FACTORS
Endothelial cells cause vasodilatation in response to increases
in flow, shear stress and agonists through the release of
several mediators, which include prostaglandin I2, endo-
thelium-derived hyperpolarizing factor and NO. The formation
of NO by NO synthase (NOS) in the vascular endothelium
from the amino-acid L-arginine has opened up a new area of
biological research. Several forms of NOS have been
identified; endothelial NOS regulates endothelial function
and vascular tone, whereas the neuronal isoform of NOS
(nNOS) modulates SNS activity.
Impaired endothelium-dependent vasodilation has been
observed in CKD and ESRD patients.43,44 In 5/6 NPX rats,
Vaziri et al.45 observed downregulation of endothelial and
inducible NOS, and suggested that this may contribute to the
BP elevation. Chronic inhibition of NO synthesis by NG-
nitro–L-arginine methyl ester (L-NAME) has been used as a
model of arterial hypertension in animals. Administration of
nitro-L-arginine to rats causes systemic hypertension, marked
renal vasoconstriction and hypoperfusion, as well as a fall in
glomerular filtration rate.46 Sakuma et al.47 have also shown
that the increase in renal SNS activity and in BP after
administration of NG-methyl-L-arginine (NOS inhibitor) to
male Wistar rats could be reduced by spinal C1–C2
transection, implying that NO may play a role in the central
regulation of SNS tone. nNOS is present in a specific area of
the brain involved in the modulation of the noradrenergic
control of BP48,49 and is an important component of
transduction pathways that tonically inhibit SNS activity.3
A decrease in central nNOS may result in greater SNS activity
and BP. However, in Sprague–Dawley 5/6 NPX rats, we
observed that nNOS mRNA gene expression and NO2/NO3
content were increased in several brain nuclei involved in the
noradrenergic control of BP. L-NAME increased BP and NE
turnover rate in those brain nuclei. These studies suggest that
the increase in central SNS activity in chronic renal failure
rats may be partially mitigated by increased expression of
nNOS mRNA in the brain.3 Some evidence also indicates that
NO may modulate peripheral sympathetic neurotransmis-
sion.50
Vallance et al.49 have shown both in vitro and in vivo that
NO synthesis can be inhibited by an endogenous compound,
NGNG-dimethylarginine (asymmetrical dimethylarginine).
ESRD patients on chronic hemodialysis display significantly
higher plasma levels of asymmetrical dimethylarginine
and significantly lower plasma arginine-to-dimethylarginine
ratio, suggesting asymmetrical dimethylarginine may con-
tribute to hypertension in these patients.48 In CKD patients,
asymmetrical dimethylarginine levels correlated with severity
of atherosclerosis,51 cardiovascular events and mortality.52
ROLE OF ARTERIAL STRUCTURAL CHANGES
The importance of large artery function has also been
recognized as a factor contributing to hypertension and
cardiovascular disease. The distensibility of large vessels
serves as a protective mechanism. The heart generates a large
forward pressure wave distending the aorta, creating a
reflection wave that increases diastolic coronary perfusion
and dampens the pressure on the distal microcirculation,
preventing mechanical damage.53 Distensibility is measured
by aortic pulse wave velocity, which is simple, non-invasive,
and reproducible. Increased aortic stiffness is seen with
advancing age, smoking, diabetes mellitus, and CKD, and it is
recognized as an independent predictor of cardiovascular risk
in hypertensive54 and CKD patients.55 Increased aortic
stiffness coincides with elevation in systolic BP, and an
elevated pulse pressure, which is a strong predictor of
cardiovascular mortality in ESRD patients.56 The two factors
that determine distensibility are pressure and the vessel wall
structure. The layer of smooth muscle in the vessel wall is
substantial, and is regulated by multiple factors including but
not limited to sympathetic tone, catecholamines, and
endothelial-derived vasoactive substances including NO and
ET-1. Uremic patients and laboratory animals with CKD
manifest both functional and morphologic changes of
resistance arteries, which affect distensibility.57 Morphologi-
cal changes include hyperplasia of smooth muscle cells,
calcification of media and increased intima-media thickness
owing to raised extracellular matrix content. Disturbed
calcium–phosphorus balance and secondary hyperparathyroid-
ism contribute to the morphological and functional
changes of arteries.58 These structural changes may supervene
during the course of CKD and contribute to sustaining
BP, increasing its severity and reducing the response to
pharmacological interventions.
Therapeutic modalities aimed at decreasing structural
changes in the vessel wall will eventually become an essential
component of management. To date, we know that inhibitors
of the renin–angiotensin system decrease aortic collagen
production in animal models;59 statins may also decrease
arterial stiffness.60 Studies are now underway looking at
drugs that interfere with the advanced glycation end products
of collagen and hormone replacement therapy.
RENAL ISCHEMIA
The connection between atherosclerotic renal artery disease
and hypertension is well recognized. Also well established is
the pathogenic role of the renin–angiotensin system. It is also
clear that correction of a renal artery stenosis does not always
result in improvement or normalization of BP. Renal artery
stenosis, particularly if unilateral, is often an incidental
finding or plays a marginal role in hypertension associated
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with CKD. Less appreciated is the link between ischemic
nephropathy caused by microvascular renal disease and
hypertension. Ischemic nephropathy is usually defined as a
progressive decrease in glomerular filtration rate owing to
atherosclerosis of the main renal arteries. This concept is too
restrictive and it does not take into account that athero-
sclerosis of the renal microcirculation may also lead to renal
ischemia, progressive renal failure and contribute to hyper-
tension. Upregulation of the renin–angiotensin system,
hypercholesterolemia, upregulation of growth-promoting
factors (transforming growth factor-b, leptin, etc.), oxidative
stress, and inflammation may all contribute to microvascular
disease and hypertension. Microvascular renal disease may
also ensue as a result of tubulo-interstitial inflammation and
sclerosis, increased interstitial hydrostatic pressure or accumu-
lation of adipose tissue in the interstitium. The role of this
type of ischemia and the mechanisms leading to hypertension
are less known. The kidney receives a huge supply of
oxygenated blood, less than 10% of which it needs for its own
metabolic survival. Potentially, intrarenal chemoreceptors
could be stimulated by ischemic metabolites, such as
adenosine, evoking reflex increases in SNS activity and blood
pressure. Adenosine exerts an important role in the
pathogenesis of one-clip one-kidney model of hypertension
in rats.61
OXIDATIVE STRESS AND HYPERTENSION
Considerable attention has been given to the effects of short-
lived reactive oxygen species (ROS) and reactive nitrogen
species on blood pressure and cardiovascular toxicity.
Oxygen radicals and endogenous scavenging systems, such
as superoxide dismutase, modulate vascular tone and
function. ROS production is increased in several experi-
mental models of hypertension62,63 and in human hyper-
tension.64 Vaziri et al.65 have shown that ROS are increased in
uremic rats and they react with NO-producing cytotoxic
reactive nitrogen species capable of nitrating proteins and
damaging other molecules. Antioxidant therapy ameliorated
the CKD-induced hypertension, improved vascular tissue NO
production and lowered tissue nitrotyrosine. Depletion of
glutathione, an endogenous scavenger of ROS, by means of
the GSH synthase inhibitor, butathionine sulfoximine (BSO),
caused a marked elevation of nitrotyrosine, the footprint of
peroxynitrite, and marked elevation of BP in rats.66
Whether ROS in hypertension are increased as a result of
vasoconstriction or are causative remains to be determined. A
causative role is supported by evidence that scavengers of
ROS ameliorate hypertension in animal models. Agents such
as dimercaptosuccinic acid, lazaroids, cicletanine, tempol (a
superoxide dismutase mimetic), and vitamins C and E have
been utilized to successfully reduce BP in animal models of
hypertension.67,68 The exact mechanism through which
oxidative stress may raise BP has not been fully elucidated.
ROS may stimulate vascular contraction directly or through
quenching of the vasodilator NO and production of
peroxinitrite.69 One possibility is that ROS may play a role
in the regulatory processes of noradrenergic transmission in
the brain.
We have shown that tempol (4-hydroxy-2,2,6,6-tetra-
methyl piperidinoxyl), a superoxide dismutase mimetic,
when injected in the lateral ventricle of rats, increases the
abundance of IL-1b and nNOS in the posterior hypothalamic
and paraventricular nuclei, and this is associated with
reduced NE secretion from the posterior hypothalamic and
lower BP.70 In the phenol–renal injury model of hypertension
in rat, we have shown that tempol prevents the activation of
SNS and the rise in blood pressure caused by renal injury.
These data support the hypothesis that oxygen radicals may
modulate central SNS activation through regulation of local
NO production and contribute to hypertension in renal
injury models.
The role of antioxidants in the management of hyper-
tension in CKD remains speculative.
ROLE OF IATROGENIC FACTORS
Several iatrogenic factors may contribute to hypertension in
patients with CKD (Table 1). Among these, the rising use of
recombinant human erythropoietin is of concern. Recombi-
nant human erythropoietin has substantially improved the
management of anemia and reduced the risk of heart failure
in ESRD and CKD patients and perhaps retard the
progression of kidney disease and heart disease. However,
increasing the hematocrit with recombinant human erythro-
poietin can worsen BP control.71 Hypertension induced by
recombinant human erythropoietin has been attributed to
increased blood viscosity, enhanced pressor responsiveness to
NE and angiotensin-II, direct vasoconstrictor action, in-
creased cytosolic calcium, increased blood serotonin or ET-1
levels.72
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